EGFR and non-small cell lung carcinoma: Moreover, osimertinib was better tolerated, with fewer grade 3 or higher adverse effects when compared with first-generation EGFR-TKIs (34% versus 45%).6 In view of these results, osimertinib has been propelled into first-line therapy for patients with advanced or metastatic NSCLC with activating EGFR mutations, regardless of their T790M status.13 Despite these results, the possibility of sequencing treatment with first-/second-generation EGFR-TKIs followed by osimertinib could be a potential alternative with consistent data but applicable only in patients developing T790M mutation.3